Cannabis firm HEXO (NYSE:HEXO,TSX:HEXO) is coming forward with the revelation that it illegally grew cannabis in an unlicensed room in July.

After the markets closed on Friday (November 15), the Quebec-based cannabis producer informed investors that a section of one of its production facilities in Niagara, Ontario, was found to be inadequately licensed. This facility belongs to HEXO by way of its C$263 million Newstrike Brands acquisition.


Following the issue of a license for the facility in November 2018, the firm claims regulators did not indicate that a specific area, known as Block B, did not fall within the licensing segment, despite it being included as part of the original application.

HEXO states that the federal agency requested more information about that specific section of the operation, but went on to award a license for the Niagara facility.

According to HEXO, the lack of license for Block B went undiscovered in February during a facility inspection by the Canadian regulator, which failed to reveal any issues at large.

The company said it wasn’t until after the Newstrike Brands transaction closed in July that it found Block B was not fully licensed, forcing management to stop cultivation and production in the space.

“The company notified Health Canada instantly, and the regulator was satisfied with HEXO management’s corrective actions,” HEXO said in a statement, adding that cannabis from Block B was then held and scheduled for destruction.

The revelation comes after the company has suffered a variety of woes. Former CFO Michael Monahan announced his departure from the firm just five months after taking the position; this led to HEXO receiving a collection of analyst downgrades, including one from Bank of America Merrill Lynch, which changed its target to C$4 from C$9.

HEXO also withdrew its revenue outlook for 2020 in October, further driving down its value.

“While we are disappointed with what we uncovered, we assume responsibility for any issues with UP products prior to the acquisition,” said CEO Sebastien St-Louis in a statement.

This new transparency update is intended to be a proactive move on HEXO’s part, the firm said, in response to damaging “false information” being spread about the company.

St-Louis previously said the Newstrike acquisition was planned as a way to alleviate the heavy demands HEXO was facing for its products.

HEXO’s Niagara facilities aren’t currently in operation after the company announced in October it was rightsizing and eliminating 200 positions across the company.

stock chart of HEXO on the NYSE for the last five days

HEXO issues follow CannTrust illegal growing debacle

HEXO isn’t the only company in the sector to face illegal growing issues.

CannTrust Holdings (NYSE:CTST,TSX:TRST) rose to infamy in July when its facility in Pelham, Ontario, was hit with a non-compliant rating by Health Canada after an inspection revealed some of its growing rooms weren’t licensed.

Things quickly went from bad to worse once it was found that high-level executives, including former CEO Peter Aceto and former Chairman Eric Paul, knew of the illegal growing, which led to their dismissal and the subsequent suspension of the firm’s production licenses.

Since then, CannTrust has lost 78.6 percent of its value in Toronto.

While falling outside the guidelines of Health Canada may seem like the end for a producer, the regulator set a precedent by issuing a reinstatement for Winnipeg-based cannabis producer Bonify in October.

Health Canada spokesperson Eric Morrissette said in a statement that Bonify had faced contamination issues and was found to be processing and distributing cannabis product from an illegal source. The cannabis was then delivered to stores in Saskatchewan.

CannTrust similarly has placed itself on a path to attempt to regain its status as a legal producer under the approval of Health Canada. In October, the firm announced it expects to complete all the activities marked in its remediation plan by the end of Q1 2020.

“The Company has already made significant progress in this regard, and is committed to completing all of the remediation actions outlined in the plan, with input from Health Canada as appropriate,” CannTrust Chairman and Interim CEO Robert Marcovitch said in a statement.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Danielle Edwards, hold no direct investment interest in any company mentioned in this article.

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce the appointment of Mr. Al Reese, Jr., to its Board of Directors

Mr. Reese has over 40 years experience in public and private businesses including as CFO of a formerly Nasdaq-listed energy company where he arranged finance transactions totaling over $10 billion dollars during his 20-year tenure. Mr. Reese was a Director and Chairman of the Audit Committee of a community bank in Texas for ten years until such time as it was acquired by a larger banking group in 2018.

Keep reading... Show less

Mexico looks to be closer than ever to cannabis reform, with the country releasing its regulation plans to make the drug legal in medical settings.

Meanwhile, despite the financial hardships seen recently in the Canadian cannabis market, CEOs in the country are still receiving top dollar, as per a new study.

Keep reading... Show less

Not for Distribution to United States Newswire Services or for Dissemination in the United States

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today the pricing of its previously announced best efforts overnight marketed offering (the “Offering”) of subordinate voting shares (the “Offered Securities”) of the Company at a price of C$16.00 per share for a total gross proceeds of approximately US$125 Million. The issue price represents a 3.3% discount to the last close of the Company’s subordinate voting shares traded on the Canadian Securities Exchange as of January 14, 2021. 100% of the Offering is expected to be purchased by a total of seven new and existing institutional investors, including current shareholder, Wasatch Global Investors.

Keep reading... Show less

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from leaders at: Tilray, Inc. (NASDAQ: TLRY), Icanic Brands (OTC: ICNAF) (CSE: ICAN) Red Light Holland (OTC: TRUFF) (CSE: TRIP) and Aphria, Inc. (NASDAQ: APHA).

Investors are cheering new and expected legislation which is opening new market opportunities for both cannabis and psychedelics globally. Innovation in premium branding, growing technologies, manufacturing, with operational execution are key, in the drive towards profitability. Wall Street Reporter highlights the latest comments from industry thought leaders in cannabis and psychedelics:

Keep reading... Show less

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company”) today announced the closing of its previously announced underwritten public offering (the “Offering”) of 1,828,571 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock at a public offering price of $5.25 per unit (all prices in US$). The warrants have an exercise price of $6.58 per share, are immediately exercisable and will expire five years following the date of issuance. In connection with the Offering, the underwriter exercised in full its option to purchase an additional 274,285 shares of common stock and additional warrants to purchase 274,285 shares of common stock. The gross proceeds from the Offering were approximately $11.04 million, before deducting underwriting discounts and estimated offering expenses. No securities were offered or sold in Canada, including through the CSE or any other trading market in Canada

H.C. Wainwright & Co. (“Wainwright”) acted as the sole book-running manager for the Offering and is a non-related party to the Company.

Keep reading... Show less